91 related articles for article (PubMed ID: 22184778)
1. Urticaria pigmentosa after treatment with TNF antagonists: a case report.
Leloup P; Daviet V; Chiffoleau A; Dréno B
Arch Dermatol; 2011 Dec; 147(12):1459-60. PubMed ID: 22184778
[No Abstract] [Full Text] [Related]
2. A pilot study of etanercept treatment for pemphigus vulgaris.
Fiorentino DF; Garcia MS; Rehmus W; Kimball AB
Arch Dermatol; 2011 Jan; 147(1):117-8. PubMed ID: 21242406
[No Abstract] [Full Text] [Related]
3. Etanercept: an overview of dermatologic adverse events.
Lecluse LL; Dowlatshahi EA; Limpens CE; de Rie MA; Bos JD; Spuls PI
Arch Dermatol; 2011 Jan; 147(1):79-94. PubMed ID: 21242398
[TBL] [Abstract][Full Text] [Related]
4. [Risks and side effect reactions during therapy with TNF-alpha blockers. An immunologic analysis].
Berg PA
Dtsch Med Wochenschr; 2004 Jul; 129(30):1631-4. PubMed ID: 15257503
[No Abstract] [Full Text] [Related]
5. Nicolau syndrome following etanercept administration.
Guarneri C; Polimeni G
Am J Clin Dermatol; 2010; 11 Suppl 1():51-2. PubMed ID: 20586511
[TBL] [Abstract][Full Text] [Related]
6. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.
Keat A; Barkham N; Bhalla A; Gaffney K; Marzo-Ortega H; Paul S; Rogers F; Somerville M; Sturrock R; Wordsworth P;
Rheumatology (Oxford); 2005 Jul; 44(7):939-47. PubMed ID: 15901904
[No Abstract] [Full Text] [Related]
7. Multiple eruptive plaque-like dermatofibromas during anti-TNFα treatment.
Caldarola G; Bisceglia M; Pellicano R
Int J Dermatol; 2013 May; 52(5):638-41. PubMed ID: 22804251
[No Abstract] [Full Text] [Related]
8. Onset of lichen planus during treatment with etanercept.
Musumeci ML; Lacarrubba F; Micali G
Am J Clin Dermatol; 2010; 11 Suppl 1():55-6. PubMed ID: 20586513
[TBL] [Abstract][Full Text] [Related]
9. Resident Rounds. Part III B: tumor necrosis factor-α antagonists and alopecia areata: a class-wide adverse effect.
Griffith JL; Ledet JJ; Elewski BE
J Drugs Dermatol; 2013 Jun; 12(6):713-4. PubMed ID: 23839195
[No Abstract] [Full Text] [Related]
10. Use of etanercept in children.
Wargula JC; Lovell DJ
Bull Rheum Dis; 2000; 49(12):1-4. PubMed ID: 11314579
[No Abstract] [Full Text] [Related]
11. TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection.
Tobinick E
Curr Med Res Opin; 2004 Jan; 20(1):39-40. PubMed ID: 14741070
[No Abstract] [Full Text] [Related]
12. Peripheral mononeuropathy with etanercept use: case report.
Hanaoka BY; Libecco J; Rensel M; Hajj-Ali RA
J Rheumatol; 2008 Jan; 35(1):182. PubMed ID: 18176996
[No Abstract] [Full Text] [Related]
13. Etanercept therapy for psoriasis in a patient with numerous comorbidities.
De Simone C; Carbone A; Caldarola G
Am J Clin Dermatol; 2010; 11 Suppl 1():49-50. PubMed ID: 20586510
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of delayed pressure urticaria with anti-TNF-alpha.
Magerl M; Philipp S; Manasterski M; Friedrich M; Maurer M
J Allergy Clin Immunol; 2007 Mar; 119(3):752-4. PubMed ID: 17336621
[No Abstract] [Full Text] [Related]
15. Facial granulomatous nodules during etanercept treatment for psoriasis.
Samimi M; Lorette G; Machet L; de Muret A; Watier H; Maruani A
Int J Dermatol; 2009 Sep; 48(9):1025-7. PubMed ID: 19703000
[No Abstract] [Full Text] [Related]
16. Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis.
Soliotis F; Glover M; Jawad AS
Ann Rheum Dis; 2002 Sep; 61(9):850-1. PubMed ID: 12176818
[No Abstract] [Full Text] [Related]
17. Etanercept therapy for psoriasis in a patient with active pulmonary tuberculosis.
Huo R; Romanelli P
Am J Clin Dermatol; 2010; 11 Suppl 1():39-40. PubMed ID: 20586506
[TBL] [Abstract][Full Text] [Related]
18. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists.
Gottlieb GS; Lesser CF; Holmes KK; Wald A
Clin Infect Dis; 2003 Sep; 37(6):838-40. PubMed ID: 12955647
[TBL] [Abstract][Full Text] [Related]
19. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer.
Madhusudan S; Muthuramalingam SR; Braybrooke JP; Wilner S; Kaur K; Han C; Hoare S; Balkwill F; Ganesan TS
J Clin Oncol; 2005 Sep; 23(25):5950-9. PubMed ID: 16135466
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous drug eruption with an interface dermatitis pattern due to anti-tumour necrosis factor-alpha agents: a relevant class-effect.
Garcovich S; Burlando M; Rongioletti F; Garcovich A; Parodi A; Amerio P
Acta Derm Venereol; 2010 May; 90(3):311-2. PubMed ID: 20526559
[No Abstract] [Full Text] [Related]
[Next] [New Search]
